Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.